

Disclosure

In the interest of full disclosure I wish to communicate that I have a professional relationship with PeriGen: Chief Nursing Officer Professional Education Center: Educator

Co-author : Mosby's Pocket Guide: "Fetal Monitoring: A Multidisciplinary Approach" monetary royalties

Monitoring the Preterm Fetus

- EFM implemented to establish fetal well being
- Physiologic differences dependent on fetal development stage
- Response and/or tolerance to oxygenation pathway disruptions
 Differ from those of term fetus
- Limited interpretation research (<26 weeks)
- Presumed maturation of ANS
- ° Development of fetal cardio-regulatory mechanism at ~30 weeks
- Fetal behavior and maternal exposure literature evolving

Viability Necessitates FHR Monitoring.....

- Lower limits for viability Sophisticated NICU care leading to improved survival rates
- Preterm FM often hampers ability to collect uninterrupted data ° Inconsistent high quality tracings
- Current equipment unable to precisely determine FHR timing • Employs heart rate averaging techniques
- Antepartum FSE not practical

	20 - 21 + 6	22 -22+6	23-23 +6	24 - 24+6	25-25+6
Assess for NRP	N/R	Consider	Consider	Yes	Yes
Steroids	N/R	N/R	Consider	Yes	Yes
Tocolysis for steroids	N/R	N/R	Consider	Yes	Yes
Neuroprotection	N/R	N/R	Consider	Yes	Yes
Antibiotics for PPROM latency	Consider	Consider	Consider	Yes	Yes
Intrapartum antibiotics for Group B Strep	N/R	N/R	Consider	Yes	Yes
Csection for fetal reasons	N/R	N/R	Consider	Consider	Yes

"Continuous electronic fetal monitoring is not separately considered as an intervention because in most cases its use will be linked to plans regarding cesarean delivery for fetal indications. Even if cesarean delivery for fetal indications is not planned if arrangements have been made for resuscitation of a potentially viable live born neonate, electronic fetal monitoring may be considered if it is believed that intrauterine resuscitation will affect the newborn's outcome"

The American College of Obstetricians and Gynecologies Society for Maternal-Fetal Medicine

OBSTETRIC CARE CONSENSUS Number 3 · November 2015 Periviable Birth

How Should We Monitor?

Continuous EFM?

 \circ Some consider this to be standard in patients who are expectantly managed \circ No data to support this

Liability?

• Potential if written order not carried out

The Problem with Continuous EFM

Retrospective cohort study

Purpose: Evaluate the completeness of the record during continuous EFM $^\circ$ No previous data to support continuous EFM and liability issue if not carried out

PPROM patients being managed expectantly

47 patients

24-34 weeks gestation
 Singletons

Exclusion criteria

• Labor, chorioamnionitis or FHR abnormalities

Results

Duration of monitoring

• 321 – 2272 minutes (mean 970 minutes)

28.3% of tracings did not show legible recordings $^\circ$ 85% of uninterpretable data lasted <10 minutes

• 15% of uninterpretable data lasted 10-80 minutes

Results

- Significant portion of the tracing was not recorded as ordered $^{\circ}\,28\%$
- ° No difference in first/second half of shift
- $^{\circ}$ No difference in day shift versus night shift
- Lower EGA and increased BMI correlated to proportion of absent tracing $\,^\circ$ Average 29 4/7 weeks (24 2/7 weeks)
- Average BMI = 31.4 (58.1)

Conclusion

F-# 100 Barr		718,241,344		7140,242	345	
		- 181			1	
		- 190				
	- 197 - 5	100 8	× ~	18 1. 10		~
· m.					· 41 -	Aur.
	_					
20						
*			-256	9		
and have	- and the second	est-take	The Branning			1
	111					1.000
14 6 87 89	140		14.0.000	100		

"We propose that until such time that evidence based medicine justifies the use of continuous external fetal heart rate monitoring, alternative approaches should be investigated and applied."

Physiology: Extrinsic and Intrinsic Factors

EXTRINSIC: "OUTSIDE" INFLUENCE

Maternal and uteroplacental characteristics affect blood flow

- Maternal impact
- Uteroplacental impact
- Umbilical circulation
- Amniotic fluid features

INTRINSIC: "INSIDE" INFLUENCE

- Maintains fetal homeostasis
- Fetal circulation
- Autonomic nervous system
 Parasympathetic
- Vagus Nerve/Medulla Oblongata
 Sympathetic
- Nerve fibers of myocardium
- Baroreceptors/Chemoreceptors
- Hormonal responses

Physiologic Extrinsic Influence

Aternal influences • Positioning: compression on inferior vena cava • ↓ Venous return

- I Blood flow to uterus Contractions: I uterine blood flow
- Compensatory hypotension

Placental influences

- $^{\circ}$ Amount of surface area for maternal-fetal 02 exchange \circ Composition: damaged cotyledons, smoking, vessel constriction

Physiologic Extrinsic Influence

Umbilical Cord

 Structural defects • Knots, 2 vessel cord

Mechanical function

 \circ Partial or complete compression Amniotic Fluid

• I Placental function leads to I fetal kidney perfusion

° Shunts blood away from kidneys


Physiologic Intrinsic Influence

Intrinsic influences

Designed to interact and ensure adequate oxygenation to vital organs

Autonomic Nervous System:

° Parasympathetic and Sympathetic Responds to fetal oxygenation status and fetal blood pressure





Physiologic Intrinsic Influence

- Parasympathetic Nervous System: "Pokey"
- ° Influences FHR variability
- $^{\circ}$ PNS activity f 1 with gestational age
- \circ Tone **1** and FHR baseline **J** with advancing gestational age
- Sympathetic Nervous System: "Speedy"
- Stimulation increases FHR and may be promoted by hypoxemia ∘ FHR BL ↓ when blocked
- SNS activity ↓ with advancing gestational age

Physiologic Intrinsic Influence

Chemoreceptors

- Respond to changes in fetal O2, CO2 and pH levels
- $^\circ$ Mild increases in CO2 or decreases in O2 result in fetal BP/FHR changes
- ° Severe enough will cause bradycardia

Baroreceptors

- Stretch receptors respond to changes in fetal BP ° Located in aortic arch and carotid arteries
- Increases in BP decrease FHR resulting in BP decrease
- Decreases in BP stimulates an increase in FHR

Physiological Influences

- Hormonal (epinephrine, norepinephrine, vasopressin)
- Respond to stressors which impact FHR
- Stress caused by \$ PO2 & pH (hypoxemia and/or hypovolemia)
- Epinephrine/norepinephrine are released
- $\,{}^{\circ}\,{\sf FHR}$ $\pmb{1}$ and blood is shunted to brain/heart
- Vasopressin is released
- Impacts fetal kidneys intravascular volume and peripheral resistance • 1 fetal BP

Oxvg	enation Path	าพลง		Environment Lungs
Pathway	Etiology	Treatment		Heart Vasculature
Lungs	Respiratory depression	Oxygen	Oxygen	Uterus Placenta
Heart	Regional anesthesia	Treat with Rx, fluids	Pathway	Cord
Vasculature	Hypovolemia	Fluids, position change		
Uterus	Tachysystole	Decrease stimulants	Fetal	Fetus Hypoxemia
Placenta	Abruption	Delivery	Response	Нурохіа
Umbilical Cord	Compression	Amnioinfusion		Metabolic acidosis Metabolic acidemia
lier, L.A., Miller, D.A. and Cypher, R evier Health Sciences	L., 2016. Mosby's pocket guide to fetal manif	oring: a multidisciplinary approach.		Potential


Fetal Heart Rate Baseline

Mean FHR rounded to increments of 5 bpm during a 10 minute window Excludes

Periodic or episodic changes
 Marked FHR variability (>25 bpm)

Minimum of 2 minutes of identifiable baseline • Can be determined between contractions • Does not need to contiguous

Normal 110-160 bpm



Development of FHR Patterns During Normal Pregnancy

43 low risk women in $2^{nd}/3^{rd}$ trimester

- Synchronized recordings in 4 week intervals
- $^\circ\,\text{EFM}$ for 90-100 minutes
- 9 am and 6 pm
- Ultrasound
- Fetal eye/mouthing movement, limb/body movement, fetal breathing

Results: Baseline Rate

Negative correlation with gestational age Mean fall in baseline: 16 weeks to "term"

• 24 bpm

1 bpm per week of gestational age

Rate of fall greatest between 16-20 weeks

Less marked in last trimester

• Establishment of rest/activity cycles

Development of FHR Patterns During Normal Pregnancy

Nulliparous women at 13 weeks (7) and 20-22 weeks (10)

Real-time ultrasound

- Observations at 0800, 1300, and 2200
- ∘60 minutes = 13 weeks
- ° 120 minutes = 20-22 weeks
- °24 hours of FHR 20-22 weeks

Results: Diurnal Variations

DIURNAL 13 weeks

No variations

20-22 weeks

- "Significant" changes
 Movement and breathing
- Highest in evening
- Breathing related to maternal meals
- Lowest after 3rd meal

Results: Heart Rate Patterns (20-22 weeks)

Decels more frequent than accels Accelerations

Decelerations

Г

° 25-40 ms (10-15 bpm)


• 162/163 tracings

Exceeding 40 ms
 147/163 tracing

• 25-40 ms • 115/163 tracings • Exceeding 40 ms • 47/163 tracings

and in a

Variability		
Fluctuations in FHR BL that are irregular in amplitude and frequency	Absent: Undetectable	
Quantified as amplitude of peak and trough • In bpm	Minimal: ≤ 5 bpm Amplitude range > undetectable	
Excludes • Periodic or episodic changes	Moderate: 6-25 bpm	
Determined in 10-minute window	Marked: > 25 bpm	muniterent of the second



Fetal Heart Rate Variability

92 singletons

- Two subgroups
- 24+1 to 32+0 weeks • 32+1 to 41+6 weeks
- Magnetocardiogram sessions
- Measurement of magnetic fields produced by FHR electrical activity

Results

Inverse relationship with gestational age

FHR Pattern I

• FHR with "small oscillation bandwidth" <5 bpm</p>

 $^{\circ}$ 24+1 to 32 +0 gestations

FHR Pattern II

FHR with oscillations >5 bpm
 >32+1 to 41+6 gestations

Acceleration

Visually apparent abrupt increase in FHR

Peak \geq 15 bpm from baseline and lasting \geq 15 seconds

Preterm gestation (32 weeks)

 \circ Peak \ge 10 bpm from baseline and lasting \ge 10 seconds

Acceleration

65 low risk women between

64 minute tracings made between 0900-1300 hours

•15 patients: 5-10 tracings between 18-41 weeks

 $^{\circ}$ 50 patients: 1-4 tracings between 18-41 weeks

- Movement recorded by nurse and patient
- Hand held sensor with response intervals of 5 seconds


Resu	lts: Inc	idence of A	Accels, F	M and EGA
Weeks Gestation	Patients	Accels over 40ms 10-15 bpm	Mean # of Accels	Mean number of movements/accels
18-22	8	0	0	
23-26	5	2 (40%)	0.8	62
27-28	13	9 (30%)	2.9	43
29-30	15	10 (66%)	3.9	38
31-32	21	19 (95%)	5.4	40
33-34	28	25 (89%)	8.7	39
35-36	38	38 (100%)	14.5	43
37-38	43	43 (100%)	14.9	61
39-40	22	21 (95%)	16.0	50
41	3	3 (100%)	25.7	57

Decelerations

Most frequent between 20-30 weeks Absence of uterine contractions

Fetal movement

Reflection of developing cardioregulatory mechanisms and CNS maturity




Accelerations and Decelerations

- Low risk patients 20-22 weeks (10 patients)
- ° 28-30 weeks (10 patients)
- Fetal monitoring

- Day sessions lasting 1-2 hours in quiet room 1-2 hours after a meal
- ° Semi-fowlers with lateral tilt

FHR Changes						
EGA	Minutes monitored	Accels	Decels	Accels/Decels		
20-22 weeks	964	1.3 %	97.1%	1.6%		
28-30 weeks	1012	35.8%	33.9%	30.3%		

FHR Cha	nges with F	etal Movem	ent
EGA	Accels	Decels	Accels/Decels
20-22 weeks	62.5%	62.8%	40%
28-30 weeks	94.6%	60.3%	90.6%



FHR Patterns at 20 to 24 weeks gestation

Study aim:

Describe early patterns of FHR recorded by transabdominal fetal electrocardiogram

281 recordings

° Success rate of the recordings was 95.4

Results

- 20-24-week fetus demonstrates FHR patterns with more accelerations and decelerations
- Higher baseline variability

APFT

24-28 weeks: 50% of NSTs are not reactive (Bishop, 1981)

28-32 weeks: 15% of NSTs are not reactive (Macones, 2008; Lavin, 1984; Druzin, 1985) Variable decelerations are found in ~50% of NSTs (Meis, 1986)

200 200 100	20 20 10	140 170 900	200 270 110 110 110	20 20 00
120	130	120	120	130
	*	*	9)	
0		ŵ	0	¢
74175	30 74176	\$ 74177	30 74178	. % 74179
			100 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	


What is Normal?


Study Aim

- 43 low risk singleton pregnancies in 2^{nd} and $3^{rd} \ trimester$
- 22 primips and 21 multips
- Fetal monitoring in 4 week intervals and real
- time ultrasound
- Establish normal pattern development and relationship to activity and behavior 43 Jow risk signal-1

Biophysical characteristics

- Accelerations: 15x15 Decelerations: ↓ FHR at least 15 bpm below baseline lasting 10 seconds
- "Average variability"





RCT comparing criteria

Objective

• Compare outcomes at <32 weeks using 10x10 and 15x15 criteria

- 143 singleton high risk patients
- NST 20 minutes

• Nonreactive: VAS followed by 20 more minutes; not reactive BPP Conclusion

- $^\circ$ Time to achieve reactive NST 4 minutes shorter in 10x10 group
- ° No adverse outcomes in either group

-Considering the low incidence of adverse events after outpatient NST at 32 weeks' gestation, the authors suggest that it would be difficult to test this question in a prospective randomized study with anything other than a very large multicenter trial. A power analysis (alpha, .05; beta, 80%) indicated a total sample size of 8856 would be needed to find a difference in 5-minute Apgar scores of 7 or a total sample size of 7528 to detect a difference in neonatal intensive care unit admissions."

Preterm NST

Objective

 $^\circ$ Evaluate perinatal outcome <32 weeks $\,$ between 10x10 and 15x15 $\,$

Retrospective review

Singleton pregnancies between 23-32 week and delivered before 34 weeks 751 NSTs reviewed on 488 women (mostly inpatient)

Results

After adjustment for EGA / BW , there was NO association between NST criterion and outcomes except between nonreactivity and perinatal death

If the perinatal death rate in the 10x10 group is estimated to be 10%, an adequately powered study would require 2000 patients in each arm to demonstrate a 25% difference in perinatal death)

If the perinatal death in the 10x10 group is estimated to be 1%, more than 21,000 patients would be needed in each group to demonstrate a 25% difference

D. A. Miller, MD



FHM and Medications in the Preterm Fetus

- Magnesium sulfate
- Decreases variability
- $^\circ\,\mbox{Decreases}\,$ acceleration amplitude

Corticosteroids

- Decreases variability
- Decreases biophysical characteristics
- Progesterone
- None reported

- Beta sympathomimetics
- Tachycardia
 Mother and fetus

Prostaglandin inhibitors • None reported

 Constriction of ductus arteriosis

Calcium channel blockers • None reported

Magnesium Sulfate

Study

Crowthe

Rous

- Neuroprotection prior to preterm birth • Neuroprotective intent
- Reduce vascular instability, lessen hypoxic damage, and protect against cytokine or amino acid damage
- Pre-delivery magnesium (<32 weeks)
 Reduces severity and risk of cerebral palsy

er	4 gram load followed by 1 gram/hour	Up to 24 hours
	6 gram load followed by 2 grams/hr	Up to 12 hours; treatment resumes when delivery is imminent

Duration

Effect of Magnesium Sulfate on FHR Parameters: A Systematic Review

Study Objective

• Examine potential effects on ante/intrapartum EFM

Systematic review

• 18 RCTs, observational studies, case studies

• FHR BL, variability and acceleration-deceleration patterns

Results

- Statistically significant decrease in FHR
- Up to 15 bpm
- $^{\circ}$ All remained in normal range 110-160 bpm
- Decrease in FHR variability
- Decrease in acceleration number and/or frequency $\,^{\circ}$ No more than 5 10 bpm

Effects of Magnesium Sulfate On Cerebral Blood Flow

38 patients

- Singletons/twins (24-31 weeks EGA)
- 18 Magnesium Sulfate (Rouse protocol)
- 10 Placebo
- Middle cerebral artery measurements
- \circ Before medication administration
- $^\circ$ 1, 2, 3, and 4 hour intervals

Results

Decrease in FHR baseline (doppler waveforms)

- 8-10 bpm
- No significant difference
- Peak systolic velocity
- Vessel diameter
- Volume flow
- Conclusion
- ° No significant effects on fetal cerebral blood flow

The Effect of Magnesium Sulfate On FHR Parameters

34 patients

> 30 weeks EGA (nonlaboring)

800 kcal meal

Randomized

- Magnesium Sulfate (6 gram load and 2 gram/hr) Placebo
- One hour monitoring sessions ° Baseline, 1 hour and 3 hours of infusion

Res	ults				
	FHR	Group	0 hour	1 hour	3 hour
	Baseline	Placebo	134.4 ± 6.3	134.4 ±7.1	134.6 ±7.1
		Mag Sulfate	136.6 ± 6.4	135.1 ± 6.6	132.3 ± 7.6
	Variability	Placebo	2.75 ± 0.33	2.81 ± 0.30	2.71 ± 0.52
		Mag Sulfate	2.82 ± 0.29	2.84 ± 0.28	2.67 ± 0.36
	Accels	Placebo	10.2 ± 8.3	10.3 ± 8.2	10.4 ± 6.9
		Mag Sulfate	11.1 ± 6.2	10.3 ± 8.2	7.4 ± 4.1

Corticosteroids for Fetal Maturation

- Single course
- Risk of PTD within 7 days
- ° 23/24 to 34 weeks Later EGA's

Betamethasone

 $^\circ\,12\ mg\ q24h\ x2$

Dexamethasone $\circ 6 \text{ mg q12 x 4 doses}$ Treatment <24h has some benefit

- No additional benefit to "accelerated dosing" (q week) • Giving doses at shorter intervals
- Rescue dose
- ° Initial treatment >2 weeks prior
- Likely to deliver w/in 1 week & <34 wks
- Single course

Betamethasone Administration

31 women who had received 2 doses for PTL $^\circ$ Gestational age: 26-32 weeks

Daily EFM for 5 successive days (0-4) • 30-60 minutes

Ultrasound (Days 0, 2 and 4)

• Fetal body movement, breathing, eye movements

Results

FHR variability below normal range for EGA • 1/3 cases

Body movement

• Reduced by 50% on Day 2 Breathing movement

Absent on Day 2

Eye movements: unchanged Day 4: return to normal state

Considerable decrease in biophysical characteristics • Except eye movement Transient reduction in movements and activity

? Glucocorticoid receptor mediated process

Corticosteroids and BPP/Doppler Indices

35 singleton pregnancies

° 28-34 weeks

Betamethasone

Biophysical profile and dopplers

• Pre-steroid

° 24, 48, 72, 96 and 120 hours after 1st dose

Results

Reduced biophysical characteristics ° Movement, fetal breathing & reactivity

Amniotic fluid index unchanged ° Not volume

Fetal tone unchanged

Umbilical artery & middle cerebral artery



Specific Biophysical Scores

Pre steroid: 10 24 hours: 8 48 hours: 6 (maximum peak of steroid) 72 hours: 8 96 hours: 10 120 hours: 10

Preterm Fetal Heart Rate Assessments

Rate


Variability Periodic and Episodic Changes Uterine Activity Pattern Evolution Associated Clinical Findings Urgency Communication Use of Health Information Technology




"There must be a balance between knowledge, expert skills, clinical intuition and the benefits of technology. The perception that technology will take over clinical responsibilities, such as FHR interpretation, leaving all data to be interpreted, documented and managed by artificial intelligence is not only incorrect but illogical. "



R. Cypher, MSN, PNNP August 2016



Risk Antepartum Care				
Nurse-to-Woman or Nurse-to-Baby Ratio	Care Provided			
Antepartum				
1 to 2-3	women during nonstress testing			
1 to 1	woman presenting for initial obstetric triage			
1 to 2-3	women in obstetric triage after initial assessment and in stable condition			
1 to 3	women with antepartum complications in stable condition			
1 to 1	woman with antepartum complications who is unstable			
1 to 1	continuous bedside attendance for woman receiving IV magnesium sulfate for the first hour of administration for preterm labor prophylaxi and no more than 1 additional couplet or woman for a nurse caring for woman receiving IV magnesium sulfate in a maintenance dose			
	women receiving pharmacologic agents for cervical ripening			



Thank You! rlcjumper@aol.com



Birth is the sudden opening of a window, through which you look out upon a stupendous prospect. For what has happened? A miracle. You have exchanged nothing for the possibility of everything. William MacNeile Dixon, 1866 - 1946